Dr. Chagpar Discusses the Impact of Lifestyle Changes on Reducing Breast Cancer Risk
Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, explains how lifestyle changes that align with the US Cancer Prevention Guidelines can reduce one's breast cancer risk.
Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, explains how lifestyle changes that align with the US Cancer Prevention Guidelines can reduce one’s breast cancer risk.
Chagpar says different studies have had different results on how diet, exercise, and obesity impact the risk of breast cancer. However, researchers have estimated that making these changes can result in a 10% reduction of risk.
By eating healthy, exercising, and limiting alcohol intake, individuals can help reduce their risk of developing breast cancer, which is the leading malignancy of women in the US, Chagpar says.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
